

Gateway | – Inaugural GAP Award

ABOUT US

[Gateway for Cancer ResearchSM](#) is a nonprofit 501c (3) organization committed to funding innovative cancer research that helps people living with cancer to feel better and live longer as we work to end cancer as we know it. Thanks to generous underwriting, 100% of every dollar Gateway receives directly funds Phase I and Phase II cancer clinical trials at leading research institutions around the world. Since its inception in 1991, Gateway has invested more than \$110 million to more than 225 cancer clinical trials. These studies have offered hope and healing to more than 8,500 cancer patients, altered the standard of care at some of the world's most trusted health care institutions, and contributed to the development of new FDA-approved cancer treatments and therapies.

PURPOSE

Gateway is dedicated to supporting the next generation of academic-based clinical investigators who are developing investigator-initiated trials (IITs). At our follow up Gateway Clinical Trial Accelerator Program (GAP) session, applicants will have the opportunity to pitch their novel IIT idea live in front of members from the Gateway Scientific Peer Review Committee and clinical trialists with a chance to win the \$50,000 GAP Award.

Focus Areas:

We advance our mission by funding early phase clinical trials focusing on the following:

- New Investigational Therapies
- New Indications
- Mitigation of Treatment Toxicity
- De-escalation of Treatment
- Predictive Biomarkers (with a therapeutic component)
- Integrative Medicine

In these research areas:

- Biomarkers (prognostic or predictive with supportive treatment)
- Gene Therapy
- Immunotherapy
- Targeted Therapies

Non-fundable Areas:

Gateway does not fund any of the following:

- Basic laboratory research
- Pre-clinical animal research
- Device testing studies
- Early prevention or early detection studies
- Retrospective, non-interventional, observational, or certain phases of translational studies
- Educational studies
- Comparative effectiveness research (CER) studies
- Dose-ranging pharmacokinetics that do not include clinical efficacy measures

Correlative studies using human bio specimens may be considered if:

- If they impact decision making for patient care.

FUNDING AVAILABLE

Gateway will provide a \$50,000 USD grant in funding for direct costs of the research for the facilitation of a study start-up.

Please submit your LOI on our [grant management system](#) and select **“GAP Award”** during the eligibility quiz. Please email research@gatewaycr.org with any questions about LOI completion. You will then be notified if you are chosen to pitch your LOI onsite at the ASCO Annual Meeting in Chicago, IL on Saturday, June 1. Those who attended the first GAP workshop will be prioritized if their LOI is selected. During the event, you will have 4 minutes (or more) to pitch your LOI in person and the applicant with the highest score will be awarded a \$50,000 grant.

KEY DATES

GAP application opens:	March 4, 2024
LOI due:	April 22, 2024
Invitation to pitch LOI:	May 20, 2024
In-person LOI pitch:	June 1, 2024, from 11:00 am to 1:00 pm CST
Notification of award:	June 1, 2024
Grant Term:	One Year

ELIGIBILITY

Applications may be submitted by entities that engage in cancer research including:

- Higher Education Institutions
- University Medical Centers
- Nonprofits Other Than Institutions of Higher Education
- Government Organizations (may include medical centers and hospitals that have access to resources and infrastructure to support a research project)
- Foreign Institutions are eligible to apply

The sponsoring organization must have a track record in scientific leadership, collaboration, and demonstrate depth and breadth in its research. The organization must ensure support for the proposed research project. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and resources that can contribute to the planning process and implementation of the project. The sponsoring organization must ensure to provide protected time to the Principal Investigator.

Principal Investigators (PIs)

- Must have a doctoral degree (including MD, PhD, MD/PhD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent doctoral degree) in the biomedical sciences.
- **Must be able to attend the live session being held at the Hyatt Regency McCormick Place (the hotel attached to McCormick Center where the 2024 ASCO Annual Meeting is being held).**
- **Must be an Assistant Professor or institutional equivalent at the time of application**
- Must be a full-time employee of the sponsoring institution.
- Physicians must have a valid, active medical license in the country where the research will be conducted at the time of application and during the entire period of the grant.
- Be able to commit sufficient time and effort to assure successful progress of the clinical trial (applies to total research, not just the proposed project) during the award period.

- Postdoctoral or clinical research fellows or the equivalent who are working under the auspices of a scientific mentor are not eligible to apply.
- There are no citizenship or geographic requirements. However, by submitting an application, an applicant applying from an institution located in a country in which he/she is not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which he/she applied.